Licensing status

Publication and contact information



IL-17A; IL-17 receptor C (IL17RC); VEGF

Mouse studies suggest IL-17A inhibitors could help treat VEGF inhibitor−resistant cancers. In mouse models of murine lymphoma, Il-17a levels were higher in VEGF inhibitor−resistant tumors than in VEGF inhibitor−sensitive tumors. In mice with resistant lymphomas treated with anti-Vegf antibody, Il17rc deficiency or co-treatment with an anti−Il-17a antibody decreased tumor growth compared with intact Il17rc or no co-treatment. Future studies could include testing IL-17A inhibitors in models bearing VEGF inhibitor−resistant xenograft tumors.
At least eight companies have antibodies against IL-17A or IL-17 receptor (IL17R; IL17RA) in Phase I through Phase III testing to treat multiple autoimmune and/or inflammatory indications (see IL-17 inhibitors: good news, bad news, page 7) .

SciBX 6(31); doi:10.1038/scibx.2013.825
Published online Aug. 15, 2013

Patent and licensing status undisclosed

Chung, A.S. et al. Nat. Med.; published online Aug. 4, 2013;
Contact: Napoleone Ferrara, University of California San Diego, La Jolla, Calif.